Client
Lumida Wealth Management LLC 2026. All rights reserved.
The world is witnessing a demographic shift. The Baby Boomer generation, a significant portion of the population, is transitioning into retirement. In the United States, people over 65 are projected to outnumber those under 18 by 2034. With this shift comes a myriad of investment opportunities, especially in the healthcare and biotechnology sectors.
For individuals and institutions, this presents a unique chance to tap into markets poised for exponential growth.


Longevity brings with it a burgeoning demand for specialized care and assisted living facilities.
Private REITs, especially those focusing on this demographic, are one way investors gain exposure to this trend.

Innovations like CRISPR, AI-driven drug discovery, and protein folding technologies are ushering in a new era of medical advancements. The sector's vast project landscape and outcome dispersion create opportunity for active managers, especially through long/short equity strategies.
The cost of genome sequencing has plummeted, revealing insights into disease causation. New modalities, from mRNA to cell and gene therapy, are not just theoretical but are backed by successful drugs.


Some biotech indices are down as much as 50% from their 2021 peak. Yet, the sector's fundamentals remain robust, driven by new modalities and successful drug innovations.
The biotech sector has weathered storms before, like the hype around genomics in the early 2000s. Yet, it has always rebounded, driven by genuine innovations and market demand.

The Total Addressable Market (TAM) for the healthcare sector is vast. Yet, the industry has been somewhat sluggish in adopting new technologies. Emerging trends, such as telemedicine, physician practice teams, and the increasing role of nutrition in functional medicine, are reshaping healthcare delivery.
For investors, this translates to opportunities in ventures at the intersection of technology and healthcare.